1. Home
  2. CRMT vs NMRA Comparison

CRMT vs NMRA Comparison

Compare CRMT & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRMT
  • NMRA
  • Stock Information
  • Founded
  • CRMT 1981
  • NMRA 2019
  • Country
  • CRMT United States
  • NMRA United States
  • Employees
  • CRMT N/A
  • NMRA N/A
  • Industry
  • CRMT Other Specialty Stores
  • NMRA
  • Sector
  • CRMT Consumer Discretionary
  • NMRA
  • Exchange
  • CRMT Nasdaq
  • NMRA Nasdaq
  • Market Cap
  • CRMT N/A
  • NMRA 287.6M
  • IPO Year
  • CRMT N/A
  • NMRA 2023
  • Fundamental
  • Price
  • CRMT $49.61
  • NMRA $0.64
  • Analyst Decision
  • CRMT Hold
  • NMRA Buy
  • Analyst Count
  • CRMT 2
  • NMRA 8
  • Target Price
  • CRMT $50.00
  • NMRA $9.29
  • AVG Volume (30 Days)
  • CRMT 61.0K
  • NMRA 876.3K
  • Earning Date
  • CRMT 06-17-2025
  • NMRA 05-12-2025
  • Dividend Yield
  • CRMT N/A
  • NMRA N/A
  • EPS Growth
  • CRMT N/A
  • NMRA N/A
  • EPS
  • CRMT 1.04
  • NMRA N/A
  • Revenue
  • CRMT $1,380,231,000.00
  • NMRA N/A
  • Revenue This Year
  • CRMT N/A
  • NMRA N/A
  • Revenue Next Year
  • CRMT $5.39
  • NMRA N/A
  • P/E Ratio
  • CRMT $46.31
  • NMRA N/A
  • Revenue Growth
  • CRMT N/A
  • NMRA N/A
  • 52 Week Low
  • CRMT $36.40
  • NMRA $0.62
  • 52 Week High
  • CRMT $72.26
  • NMRA $17.19
  • Technical
  • Relative Strength Index (RSI)
  • CRMT 58.55
  • NMRA 27.87
  • Support Level
  • CRMT $46.44
  • NMRA $0.73
  • Resistance Level
  • CRMT $49.51
  • NMRA $0.72
  • Average True Range (ATR)
  • CRMT 1.68
  • NMRA 0.06
  • MACD
  • CRMT -0.03
  • NMRA 0.02
  • Stochastic Oscillator
  • CRMT 62.62
  • NMRA 4.91

About NMRA Neumora Therapeutics Inc.

Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has rapidly scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. The company expects to continue to progress in the development of its pipeline with the planned initiation of multiple clinical trials across its programs over the next 12 to 18 months, which supports numerous anticipated data readouts.

Share on Social Networks: